News from the 83rd Conference of the American Diabetes Association

Česká verzia

Authors: Ivan Tkáč
Authors place of work: Excelentný tím pre výskum aterosklerózy (EXTASY), LF UPJŠ v Košiciach
Published in the journal: Forum Diab 2023; 12(3): 111-114
Category:

Zdroje

Aroda VR, Aberle J, Bardtrum L et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet 2023; 402(10403): 693–704. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(23)01127–3>-
Knop FK, Aroda VR, do Vale RD et al. [OASIS 1 Investigators]. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 402(10403): 705–719. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(23)01185–6>.
Wharton S, Blevins T, Connery L et al. [GZGI Investigators]. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med 2023; 389(10): 877–888. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2302392>.
Frias JP, Deenadayalan S, Erichsen L et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet 2023; 402(10403): 720–730. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(23)01163–7>.
Garvey WT, Frias JP, Jastreboff AM et al. [SURMOUNT-2 Investigators]. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023; 402(10402): 613–626. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(23)01200-X>.
Le Roux C, Steen O, Lucas KJ et al. A phase 2, randomized, double-blind, placebo-controlled, dose-finding study of BI 456906 in people with overweight/obesity. Diabetes 2023; 72(Suppl 1): 51-OR. Dostupné z DOI: <https://doi.org/10.2337/db23–51-OR>.
Rosenstock J, Frias J, Jestreboff AM et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 2023; 402(10401): 529–544. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(23)01053-X>.
Jestreboff AM, Kaplan LM, Frias JP et al. [Retatrutide Phase 2 Obesity Trial Investigators]. Triple-hormone-receptor agonist retatrutide for obesity – a phase 2 trial. N Engl J Med 2023; 389(6): 514–526. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2301972>.
Rosenstock J, Bain SC, Gowda A et al. [ONWARDS 1 Trial Investigators]. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Engl J Med 2023; 389(4): 297–308. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2303208>.
Lingvay I, Asong M, Desouza C et al. Once-weekly insulin icodec vs once/daily insulin degludec in adults with insulin-naive type 2 diabetes: The ONWARDS 3 Randomized Clinical Trial. JAMA 2023; 330(3): 228–237. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2023.11313>.